Publications
Read their latest work
Video
Slimming down costs: MFPs and anti-obesity models unpacked
10 December 2025 - by Katherine M. Holcomb, Massey S. J. Whorley, James Cooper, Madeleine Feller
Gain timely insights into the upcoming Medicare Part D Maximum Fair Prices (MFP) for 2026 and 2027. Explore how these changes will impact coverage, access, and the competitive landscape for generics and biosimilars. Plus, discover the transformative power of anti-obesity demonstration models and what they mean for the future of healthcare.
Article
Site-neutral payment: 5 considerations for hospitals and health systems
29 September 2025 - by Rebecca Smith, Massey S. J. Whorley, Isabelle Creavin
We discuss the potential impact of policies aimed at standardizing reimbursement for comparable services across healthcare settings.
Article
Most-Favored-Nation Executive Order: 6 considerations for life science companies
17 July 2025 - by Massey S. J. Whorley
After Trump’s executive order calling for most-favored-nation pricing for prescription drugs, we highlight six considerations for life science companies.
Article
最恵国待遇（MFN）大統領令（EO）：ライフサイエンス企業が考慮すべき６つのポイント
17 July 2025 - by Massey S. J. Whorley
トランプ大統領による処方薬の価格に関する最恵国待遇を求める大統領令の発令を受け、ライフサイエンス企業が考慮すべき6つのポイントをお伝えします。